Evaluation of the safety and effectiveness of intradermal administration of QR678 Neo® hair growth factor formulation: A phase‐IV, open‐label, single‐arm multi‐ethnicity clinical trial. (8th January 2022)

• Record Type: Journal Article
• Authors: Clinic, Aayna; Asper, Annette; Mittal, Apoorva; Shome, Debraj; Parbhoo, Deepa; Thanzama, James; Doshi, Komal; Sachde, Neha; Gaunkar, Ridhima; Kapoor, Rinky; Thakkar, Rukshmani; Sion, Simal; Shetty, Sushant; Kumar, Vaibhav; Parveen, Veena; Singhal, Vivek
• Is Part Of: Journal of cosmetic dermatology. Volume 21:Number 2(2022)
• Page Start: 580
• Page End: 589
• Publication Date: 2022-01-08
• Subjects: androgenetic alopecia -- QR678 Neo®; Hair re‐growth; Skin -- Diseases -- Treatment -- Periodicals; Lasers in surgery -- Periodicals; Skin -- Pathophysiology -- Periodicals; Surgery, Plastic -- Periodicals; 616.5
• DOI: 10.1111/jocd.14715
• Languages: English
• ISSNs: 1473-2130

Abstract

Abstract: Background: Intradermal administration of QR678 Neo ® hair re‐growth factor formulation has already proven its effectiveness and safety in treating androgenetic alopecia and female pattern hair loss. Aim: This study aims to evaluate effectiveness and safety of hair re‐growth factor formulation at multiple centers for reduction of hair fall and regrowth of hair in androgenetic alopecia and female pattern hair loss. Materials and methods: An open‐label, prospective, and interventional study was carried out at multiple centers of different countries. A total of 2428 patients with androgenetic alopecia and female pattern hair loss within the age range of 18–65 years were included in the study. Hair pull test, global photographic assessment, videomicroscopic assessment tests were performed at the beginning, after fourth and eighth sessions, and self‐assessment through questionnaire related to satisfaction and side effects was carried out at beginning and at after eight session. Results: Hair pull test was positive in only 12% of the patients after eight sessions. Beneficial results were noted in the global assessment score (mean‐6) after fourth session and eighth session (mean‐8). Huge improvement was noted in terminal hair count, vellus hair count, and hair density after eighth sessions. Also, with self‐assessment score, a higher satisfaction score was noted. On long‐term follow‐up as well, no side effects were noted. Conclusion: Intradermal administration of QR678 Neo ® is an innovative, efficacious, and safe technique for the treatment of androgenetic alopecia and female pattern hair loss.